CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.
Medical devices has become a difficult place to invest but potentially all the more rewarding for those willing to take the plunge. Asia is in a prime position globally
Chinese radiotherapy business Hygeia Healthcare, which counts Warburg Pincus, Boyu Capital, and CITIC Capital among its investors, raised HK$2.22 billion ($286.4 million) in its Hong Kong IPO.
There has been a steady stream of China healthcare IPOs - most of them drug developers - on the domestic, Hong Kong and US bourses in recent months. They might be benefiting from a COVID-19 tailwind but it won't be permanent
The Carlyle Group has agreed to invest approximately $490 million for a 20% stake in pharmaceutical division of India’s Piramal Enterprises, which has interests ranging from outsourced drug development to an ophthalmology joint venture with Allergan.
The Carlyle Group is willing to invest as much as $210 million in SeQuent Scientific to get a head start in India's rapidly evolving animal healthcare industry
General Atlantic has invested $100 million in NASDAQ-listed Chinese cancer drug developer Hutchison China MediTech - also known as Chi-Med - a subsidiary of Hong Kong conglomerate CK Hutchison Holdings.
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
Genetron Holdings, a Chinese company that uses DNA sequencing to support the diagnosis and treatment of cancer, traded flat on its NASDAQ debut following a larger-than-planned $256 million IPO.
Miaoshou Doctor, a Chinese online healthcare services platform, has raised RMB600 million ($85 million) in the first tranche of Series D funding round backed by the likes of Qiming Venture Partners, Sequoia Capital China, Ince Capital Partners, CITIC...
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the diagnosis of cardiovascular diseases, has raised RMB200 million ($28 million) in an extended Series B round led by BOC International and CCB International.
BGH Capital has agreed to acquire the primary care business of Australia’s Healius – comprising medical centers, GP practices, and dental clinics – for an enterprise valuation of A$500 million ($341 million).
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, rose 49% on its trading debut following a $222.8 million US IPO.
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
CVC Capital Partners is looking to acquire majority control of Indian cancer care center operator HealthCare Global Enterprises (HCG) in a deal that could be worth up to IN10.4 billion ($$138.9 million).
Everest Medicines, a China-based biopharmaceutical company, has raised $310 million in Series C funding across two tranches.
Health and safety was a priority when IMM Private Equity negotiated a $413 million carve-out of Korea Kolmar Holdings' drug outsourcing business against the backdrop of COVID-19
Genor Biopharma, a Shanghai-based innovative drug developer, has raised $160 million in Series B funding led by Hillhouse Capital.
Mabwell Biotech, a Chinese drug developer with one treatment cleared for production, has raised RMB1.97 billion ($276 million) in Series A funding across two tranches led by specialist healthcare investor Shiyu Capital.
Chinese drug developer Jiangsu Atom Bioscience & Pharmaceutical has raised $30 million in Series B funding led by Sequoia Capital China and Hong Kong-listed Livzon Pharmaceutical Group.
MGI Tech, a Chinese manufacturer of gene sequencing devices, has raised more than $1 billion in funding led by IDG Capital and CPE.
IMM Private Equity has agreed to acquire Korea Kolmar Holdings’ pharmaceutical contract development and manufacturing organization (CDMO) for KRW512.5 billion ($413 million).